Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal

Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and definition. Establish a NASH "fibrosis reversal" pathological evaluation system, based on a new reversal standard, establish non-invasive alternative indicators, and observe indicators.

NCT Number	NCT06707129
Lead Sponsor	Beijing Municipal Administration of Hospitals
Conditions	Non-alcoholic Fatty Liver Disease
Enrollment	50 participants
Start Date	2024-08-01
Primary Completion	2027-08-31 (estimated)
Study Completion	2027-08-31 (estimated)
Updated on ClinicalTrials.gov	2024-11-27